Clinical Recommendations for a Treatment Algorithm in Pulmonary Sarcoidosis
a disease state now linked to OEF/OIF Burn pit exposure
Speaker: Franck Rahaghi, MD, MH, FCCP; Chair of Quality at Cleveland Clinic Florida Hospital and Clinic; Medical Director of the Respiratory Care Department
Description: Acthar Gel is a repository corticotropin injection that is distributed by Mallinckrodt Pharmaceuticals. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of 19 conditions, including pulmonary sarcoidosis. The ACTH hormone in Acthar Gel binds to melanocortin receptors (MCRs) in the adrenal glands on the kidneys and stimulates the production of natural corticosteroid hormones such as cortisol. These natural corticosteroids will then suppress the inflammatory and immune processes that are responsible for sarcoidosis.
Following this webinar participants will be able to:
- Understand Sarcoidosis and Athcar Gel in the treatment algorithim.
- Treat the appropriate patients with Athcar Gel within the DoD, IHS and VA Medical System.
- Know the appropriate patients and indications for Athcar Gel.
Virtual Platform: GoToWebinar
Target Audience: VA, DoD, and IHS Medical Providers
Date: Thursday, October 13, 2022
Time: 12:00pm EST
CME/CE: 0 hrs
IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder.
This webinar is sponsored by: